Joseph Rudick, M.D.

Joseph Rudick, M.D. is a Senior Scientific Advisor at Brookline, where he focuses on PIPE and private placement financings. Dr. Rudick brings together clinical medicine and biotech entrepreneurship. He has been a partner at Associate Ophthalmologists, a private ophthalmology practice in New York, and co-founded Effective Pharmaceuticals, licensee of Trimesta™ (oral estriol). He was also co-founder, Chief Executive Officer, President, and a board member of Atlantic Technology Ventures (now TG Therapeutics), where he structured a corporate partnership with Bausch & Lomb to develop Atlantic’s novel cataract removal device, Catarex™, and a partnership with Indevus Pharmaceuticals to develop IP-571, a novel clinical-stage neuropathic pain compound. Dr. Rudick has also served as Chief Medical Officer and a board member of Synthetic Biologics, and as a Vice President of Paramount Capital, where he participated in numerous technology in-licensing transactions and private equity financings.

Dr. Rudick holds a B.A. in Chemistry from Williams College, where he was elected to Phi Beta Kappa, and an M.D. from the University of Pennsylvania, where he was elected to Alpha Omega Alpha.